Wellcome

Materials and devices for bone disorders / (Record no. 504274)

MARC details
000 -LEADER
fixed length control field 04869cam a2200493Ki 4500
001 -
control field ocn962411860
003 -
control field OCoLC
005 -
control field 20190719103352.0
006 -
fixed length control field m o d
007 -
fixed length control field cr cnu---unuuu
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 161109s2017 enk o 000 0 eng d
040 ## -
-- IDEBK
-- eng
-- rda
-- pn
-- IDEBK
-- N$T
-- YDX
-- EBLCP
-- NLE
-- OCLCO
-- OPELS
-- N$T
-- OCLCF
-- OCLCQ
-- OTZ
-- IDEBK
-- OCLCQ
-- U3W
-- MERUC
-- D6H
-- YDX
-- OCLCO
-- MERER
-- OCLCQ
019 ## -
-- 962303012
-- 962326192
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780128028032
Qualifying information (electronic book)
International Standard Book Number 0128028033
Qualifying information (electronic book)
-- 0128027924
-- 9780128027929
035 ## -
-- (OCoLC)962411860
-- (OCoLC)962303012
-- (OCoLC)962326192
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
-- QP88.2
-- .M38 2017
072 #7 -
-- MED
-- 085000
-- bisacsh
082 04 -
Classification number 617.471
-- 23
245 00 - TITLE STATEMENT
Title Materials and devices for bone disorders /
Statement of responsibility, etc edited by Susmita Bose, Amit Bandyopadhyay.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource
505 0# -
Formatted contents note Front Cover; Materials and Devices for Bone Disorders; Copyright Page; Contents; List of Contributors; Biography; Preface; 1 Introduction to Biomaterials and Devices for Bone Disorders; 1.1 Introduction; 1.2 Metallic Biomaterials; 1.3 Ceramic Biomaterials; 1.4 Polymeric Biomaterials; 1.5 Composite Biomaterials; 1.6 Additive Manufacturing (AM) of Biomaterials; 1.7 Biomaterials in Orthopedic Implants Devices; 1.7.1 Joint replacements; 1.7.2 Implants used in osteosynthesis for stabilization and fracture repair; 1.7.3 Spine implants; 1.7.4 Nonconventional implants for bone tumor.
Formatted contents note 1.7.5 Multifunctional devices1.8 Summary and Future Directions; Acknowledgments; References; 2 Bone Biology and Effects of Pharmaceutical Intervention on Bone Quality; 2.1 Bone Biology; 2.1.1 Bone functions; 2.1.2 Composition; 2.1.3 Architecture; 2.1.4 Bone cells; 2.1.4.1 Osteoclasts; 2.1.4.2 Osteoblast lineage; 2.1.4.2.1 The Wnt-signaling system; 2.1.4.3 Preosteoblasts; 2.1.4.4 Reversal cells; 2.1.4.5 Mature osteoblasts; 2.1.4.6 Lining cells; 2.1.4.7 Osteocytes; 2.1.5 Bone remodeling; 2.1.5.1 The basic multicellular unit; 2.1.5.2 Sequence of bone remodeling; 2.1.5.2.1 Origination.
Formatted contents note 2.1.5.2.2 Activation2.1.5.2.3 Resorption; 2.1.5.2.4 Reversal; 2.1.5.2.5 Formation; 2.1.5.2.6 Mineralization; 2.1.5.2.7 Reestablishing osteocyte network; 2.1.5.2.8 Quiescence; 2.1.6 Fracture repair; 2.1.6.1 Stress fractures; 2.1.6.2 Complete fractures; 2.1.7 Aspects of bone strength; 2.1.7.1 Bone shape; 2.1.7.2 Bone volume; 2.1.7.3 Mineralization density; 2.1.7.4 Microarchitecture; 2.1.7.5 Collagen structure; 2.1.7.6 Ability to repair damage; 2.1.7.7 Crystal characteristics; 2.1.7.8 Bone marrow; 2.1.7.9 Overall bone strength; 2.2 Pharmaceutical Intervention.
Formatted contents note 2.2.1 Bone loss with aging or disease2.2.2 Actions of systemic hormones and local cytokines; 2.2.2.1 Estrogen; 2.2.2.2 Glucocorticosteroids; 2.2.2.3 Thyroid; 2.2.2.4 Parathyroid; 2.2.2.5 Calcitonin; 2.2.2.6 1,25 (OH)2-Cholecalciferol (1,25D); 2.2.2.7 Insulin and insulin-like growth factor; 2.2.2.8 Serotonin; 2.2.2.9 Local cytokines; 2.2.3 Calcium supplementation; 2.2.4 Bone formation with osteoporosis medications; 2.2.5 Raloxifene; 2.2.6 Bisphosphonates; 2.2.6.1 Short-term effects; 2.2.6.2 Long-term effects; 2.2.6.3 Fracture healing; 2.2.7 Denosumab; 2.2.8 Teriparatide; 2.2.9 Strontium.
Formatted contents note 2.2.10 Emerging therapies2.2.10.1 Cathepsin K inhibitors; 2.2.10.2 Romosozumab; 2.2.11 Other medications or substances that affect bone strength; 2.2.11.1 Anticonvulsants; 2.2.11.2 Selective serotonin reuptake inhibitors; 2.2.11.3 Carbonic anhydrase inhibitors; 2.2.11.4 Thiazide diuretics; 2.2.11.5 Rosiglitazone; 2.2.11.6 Bortezomib; 2.2.11.7 Lithium; 2.2.11.8 Elements toxic to the bone; 2.2.11.9 Fluoride; 2.3 Summary; References; 3 Bone Disorders; 3.1 Introduction; 3.2 Metabolic Diseases; 3.2.1 Osteoporosis; 3.2.2 Paget's disease; 3.3 Degenerative Disc Disease; 3.4 Osteoarthritis.
650 #0 -
Topical term or geographic name as entry element Bones
Topical term or geographic name as entry element Bones
Topical term or geographic name as entry element MEDICAL
Topical term or geographic name as entry element Bones
Topical term or geographic name as entry element Bones
700 1# -
Personal name Bose, Susmita,
Relator term editor.
Personal name Bandyopadhyay, Amit,
Relator term editor.
856 40 -
Uniform Resource Identifier http://www.sciencedirect.com/science/book/9780128027929
264 #1 -
-- London, United Kingdom ;
-- San Diego, CA :
-- Academic Press,
-- [2017]
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
588 0# -
-- Online resource; title from digital title page (viewed on October 26, 2018).
650 #0 -
-- Mechanical properties.
-- Diseases
-- Treatment.
-- Surgery
-- General.
-- bisacsh
-- Diseases
-- Treatment.
-- fast
-- (OCoLC)fst00836014
-- Mechanical properties.
-- fast
-- (OCoLC)fst00836023
655 #4 -
-- Electronic books.
776 08 -
-- Print version:
-- Materials and devices for bone disorders.
-- London, United Kingdom ; San Diego, CA : Academic Press, [2017]
-- 0128027924
-- 9780128027929
-- (OCoLC)954535271
856 40 -
-- ScienceDirect
Holdings
Withdrawn status Lost status Damaged status Home library Current library Date acquired Total Checkouts Barcode Date last seen Koha item type
      Mysore University Main Library Mysore University Main Library 19/07/2019   EBKELV575 19/07/2019 Ebooks

No. of hits (from 9th Mar 12) :

Powered by Koha